Wednesday, 31 May 2017

Detailed Report on Japan Market for Female Urinary Incontinence Slings 2017

Japan Market Report for Female Urinary Incontinence Slings 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The female urinary incontinence sling market in Japan differs from the global market because biological slings are not commercially available. Synthetic slings comprise almost an exclusive monopoly for the type of products offered, with autologous tissue repair accounting for a nominal percentage of total procedures. Additionally, synthetic mesh is not sold as individual kits in Japan. Hospitals purchase rolls of synthetic mesh and the physician cuts the mesh to size. The Japanese market is further differentiated by the lack of competition. Boston Scientific and Ethicon are the only two competitors offering products on the market. 
In 2016, the female urinary incontinence sling market began to recover slightly. The volatility in the market is attributed towards ongoing scrutiny by healthcare regulatory agencies such as the FDA in the United States and adverse reactions documented by the Japan Society of Obstetrics and Gynecology (JSOG). The controversy surrounding urinary incontinence slings predominantly concerns synthetic slings. Due to the negative side effects publicized about slings, however, procedures using both synthetic and biological slings have decreased globally. The adverse side-effects have resulted in patients and, to a lesser degree, physicians, becoming more cautious about sling procedures. While the repercussions of this controversy will still extend throughout the forecast period, as a result surgeons are giving greater attention to stronger patient consent protocols including full disclaimers of the risks involved.
The negative publicity regarding slings has had the greatest impact in countries without public healthcare. In Japan, there has been a faster response to treat patients with adverse effects with no additional costs for the patient. This has led to fewer lawsuits and complaints regarding the procedure helping to keep the market stable. 
Despite the contraction of the urinary incontinence sling market, the number of procedures is still substantial. The number of patients suffering from female urinary incontinence is increasing. The number of patients is also expected to continue increasing over the forecast period, as urinary incontinence affects older demographics. 
It is worth noting that biological mesh is not available for female urinary incontinence slings due to the regulatory framework for medical devices in Japan. However, even globally this segment comprises a very small portion of the overall market because many believe that collagen based mesh is not as applicable in this indication compared to other areas such as breast reconstruction or hernia repair. There is also a lack of clinical data supporting the use of biologic mesh over synthetic mesh for the treatment of stress incontinence.
Scope
2013-2023
Companies Mentioned
Kitazato Cook Medical Olympus Cooper Surgical Boston Scientific Vitrolife Irvine Scientific Naka Medical Johnson & Johnson Karl Storz Vitromed Rocket Medical Medi-Con International Carl Zeiss Sankyo Medical Pentax Life Global (IVF Online) Astec Bio The Pipette Company Esco Global Stryker Richard Wolf Merit Medical Systems BTG Leica Medtronic Others include: Nidacon Medical, Reproline Medical, ThermoFisher, AngioDynamics, Welch Allyn, local competitors, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Detailed Research on Japan Market for Pelvic Organ Prolapse Repair 2017

Japan Market Report for Pelvic Organ Prolapse Repair 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The primary driver of growth for this device market is an increase in procedure numbers, driven by an aging female demographic. However, in 2012 there was a sharp decline in procedures triggered by reports of negative and serious side effects including numerous litigations surrounding the vaginal mesh market. The majority of the concern was about transvaginal mesh. Overall, the combination of these factors has led to a stable market overall with a small growth in unit sales expected over the forecast period. 
The market has begun and is expected to continue a substantial shift from transvaginal mesh to sacrocolpopexy mesh. While transvaginal mesh sales currently comprise the majority of the market, their dominance will decrease as physicians move towards sacrocolpopexy mesh at increasing rates. While the FDA warnings issued in 2011 had the greatest effect on the United States market, the Japanese market was also impacted. Modifications to the mesh, extra clinical trials to prove safety and pre-emptive marketing is helping to clarify the safety and health risks associated with mesh to curb the decline in procedures. 
Even though the transvaginal mesh market is declining, a smaller but solid demand for this product will remain over the forecast period. ASPs for both types of mesh have been relatively stable, with a slight decline on average over the past few years. Changes in the market due to companies choosing to leave the market, notably Johnson & Johnson’s transvaginal mesh products, have created a competitive market environment as market share is reallocated. Combined with recovering unit sales, there is a high incentive to increase affordability and help procedure numbers recover through stable prices.
Scope
2013-2023
Companies Mentioned
Kitazato Cook Medical Olympus Cooper Surgical Boston Scientific Vitrolife Irvine Scientific Naka Medical Johnson & Johnson Karl Storz Vitromed Rocket Medical Medi-Con International Carl Zeiss Sankyo Medical Pentax Life Global (IVF Online) Astec Bio The Pipette Company Esco Global Stryker Richard Wolf Merit Medical Systems BTG Leica Medtronic Others include: Nidacon Medical, Reproline Medical, ThermoFisher, AngioDynamics, Welch Allyn, local competitors, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

New Report Explores on Japan Market for Fluid Management Equipment 2017

Japan Market Report for Fluid Management Equipment 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Fluid management systems can be used in conjunction with some diagnostic hysteroscopy procedures and are most recommended for use during operative hysteroscopy and endometrial resections; however, in Japan, most hysteroscopic procedures employ a gravity-fed system with saline solution. Furthermore, the number of operative hysteroscopy and endometrial resections performed annually in Japan are limited, making it difficult for hospitals or clinics to see the advantages of buying pumps or fluid management systems.
Despite the Japanese healthcare market’s predisposition towards investing in high-end, advanced capital equipment, the disciplines that are emphasized vary based on education and preferred treatment options. While the fluid management equipment market is currently in it’s infancy in Japan, it is expected to gain traction near the end of the forecast period. As more physicians realize the importance of fluid management pumps for patient safety, this market is projected to increase exponentially. Pressure-sensitive pumps reduce the flow rate when the preset level is reached, opposed to gravity bags or simple pump devices that continue to press fluid into the uterine cavity regardless of resistance. While the benefit of using pressure-sensitive pumps is less vital for diagnostic hysteroscopy and simple procedures, maintenance of a standard intrauterine pressure is essential for prolonged operative interventions. 
Asia and Oceania are transitioning from gravity bags to pumps at a much slower rate than the global norm. The consensus in Japan is that gravity bags with a pressure cuff work well enough and many hospitals and clinics feel their resources are better allocated towards other priorities. The priority of patient safety regarding fluid management is still not well emphasized. As fluid management increasingly becomes the standard of care, both in Japan and internationally, the trend from gravity bags to pumps will begin to occur at an exponential growth rate. Interestingly, there is a correlation between hysteroscopy and fluid management. Medical professionals that are trained in hysteroscopy are more likely to advocate for fluid management equipment to improve patient safety during procedures. As hysteroscopy increases in Japan, it is possible it will act as an incentive to invest in fluid management as well.
Scope
2013-2023
Companies Mentioned
Kitazato Cook Medical Olympus Cooper Surgical Boston Scientific Vitrolife Irvine Scientific Naka Medical Johnson & Johnson Karl Storz Vitromed Rocket Medical Medi-Con International Carl Zeiss Sankyo Medical Pentax Life Global (IVF Online) Astec Bio The Pipette Company Esco Global Stryker Richard Wolf Merit Medical Systems BTG Leica Medtronic Others include: Nidacon Medical, Reproline Medical, ThermoFisher, AngioDynamics, Welch Allyn, local competitors, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at 1 comment:

Research Insights on Australia Market for Uterine Fibroid Embolization Devices 2017

Australia Market Report for Uterine Fibroid Embolization Devices 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The UFE market has decreased in growth in part because of a reduction in active marketing. Moreover, UFE must compete with a wide array of procedures available to treat heavy bleeding due to uterine fibroids. These other treatments and procedures include hysterectomy, pharmacological alternatives, global endometrial ablation, endometrial resection and other minimally invasive surgical procedures. 
The complete market is comprised of the microsphere and PVA particle sub-segments respectively. Despiute the overall decrease in the market, the microspheres segment is increasing significantly. The volume of microspheres required per procedure is much higher than the volume of PVA particles required per procedure; 3.5 microspheres are used for every 2 PVA particles required per procedure. The shift towards microspheres has diminished the severity of the drop in unit sales being caused by the declining procedure numbers.
Physicians may prefer the use of microspheres over PVA particles due to peer-reviewed journals that outline how microspheres result in reduced blood loss and higher efficacy in the reduction of fibroids compared to the alternative. PVA particles have been popular in the past due to their affordability and they were previously considered the standard of care.
Scope
2013-2023
Companies Mentioned
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Recent Report on Australia Market for Colposcopes 2017

Australia Market Report for Colposcopes 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
This is a very mature and stable market, consisting primarily of replacement sales. However, there are significant variations across the sophistication and price point of the colposcopes available. The decrease is partially attributable to the majority of sales being replacements; however, there is also a slight trend to invest in resectoscopes for laparoscopic surgery as an alternative to colposcopes. 
Unit sales are largely dependent on the population of a country, since the market is largely saturated. The colposcope market is bi-modal, with a strong segmentation visible between lower-end, less expensive systems and high-end systems with advanced documentation, optics and light source. The lower-end systems are affordable options for health care facilities that are less willing or unable to purchase a high-end system at an increased expense; they are also aimed at younger physicians that are building their new practices. The high-end colposcope systems tend to be sold to larger health facilities that require robust technology capabilities and can be equipped for ceiling mounts. 
The majority of unit sales in the Australian market are for high end devices with advanced optical capabilities. Differing from the European market, smaller manufacturers based in Asia offering low-end cost-effective options have a negligible presence in the Australian market. 
In Europe, there seems to be a rising interest in colposcopy, particularly with younger physicians because it has been shown that colposcopy is able to examine changes in tissue better than cytology. This trend is forecasted to influence the Australian market by 2020 leading to a potential increase and stabilization of colposcope sales. Moreover, there is a higher interest in exams for sexual assault cases, which has benefited sales of colposcopes with documentation systems.
Most medical facilities will slowly move towards more advanced systems over the forecast period. While the ASP’s are increasing throughout the forecast period, the price of individual colposcope products is decreasing slightly. The ASP growth is generated from the transition towards higher end colposcopes from less expensive lower-end systems.
Scope
2013-2023
Companies Mentioned
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Tuesday, 30 May 2017

In-Depth Review on Australia Market for Female Urinary Incontinence Slings 2017

Australia Market Report for Female Urinary Incontinence Slings 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The female urinary incontinence sling market includes both synthetic slings and non-synthetic slings. Autologous tissue and allogenic grafts are also available options for slings; however, these treatments are not the focus of this report. The volatility in the market is attributed to ongoing scrutiny by healthcare regulatory agencies such as the FDA in the United States and adverse reactions documented by the Australian Government Department of Health TGA (Therapeutic Goods Administration). 
The controversy surrounding urinary incontinence slings predominantly concerns synthetic slings. Due to the negative side effects publicized about slings, however, procedures using both synthetic and biological slings have decreased. The adverse side-effects have resulted in patients and, to a lesser degree, physicians, becoming more cautious about sling procedures. While the repercussions of this controversy will still extend throughout the forecast period, as a result surgeons are giving greater attention to stronger patient consent protocols including full disclaimers of the risks involved.
The negative publicity regarding slings has had the greatest impact in countries without public healthcare. In Australia, there has been a faster response to treat patients with adverse effects with no additional costs for the patient. This has led to fewer lawsuits and complaints regarding the procedure helping to keep the market stable. 
Despite the contraction of the urinary incontinence sling market, the number of procedures is still substantial. The number of patients suffering from female urinary incontinence is increasing. The number of patients is also expected to continue increasing throughout the reporting period, as urinary incontinence affects older demographics. 
Biological slings procedures have been less adversely affected by the healthcare warnings. This segment comprises a very small portion of the overall market because many believe that collagen based mesh is not as applicable in this indication compared to other areas such as breast reconstruction or hernia repair. There is also a lack of clinical data supporting the use of biologic mesh over synthetic mesh for the treatment of stress incontinence.
Scope
2013-2023
Companies Mentioned
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

Detailed Report on Australia Pelvic Organ Prolapse Repair Market 2017

Australia Market Report for Pelvic Organ Prolapse Repair 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The market has begun and is expected to continue a substantial shift from transvaginal mesh to sacrocolpopexy mesh. While transvaginal mesh sales currently comprise the majority of the market, their dominance will decrease as physicians move towards sacrocolpopexy mesh at increasing rates. While the FDA warnings issued in 2011 had the greatest effect on the United States market, the Australian market was also heavily impacted. 
The impact was disproportionately higher in Anglophone countries and countries without fully public healthcare systems, possibly because of the high degree of cross-over in negative press as well as the increased patient costs associated with repeat procedures. Modifications to the mesh, extra clinical trials to prove safety and pre-emptive marketing is helping to clarify the safety and health risks associated with mesh to curb the decline in procedures. 
Even though the transvaginal mesh market is declining, a smaller but solid demand for this product will remain over the forecast period.
Scope
2013-2023
Companies Mentioned
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:

New Research Explores on Australia Fluid Management Equipment 2017

Australia Market Report for Fluid Management Equipment 2017 - MedCore is a new market research publication announced by Reportstack. 
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
The fluid management equipment market is emerging in Australia and as more physicians realize the importance of fluid management pumps for patient safety, this market is projected to grow. Pressure-sensitive pumps reduce the flow rate when the preset level is reached, as opposed to gravity bags or simple pump devices that continue to press fluid into the uterine cavity regardless of resistance. While the benefit of using pressure-sensitive pumps is less vital for diagnostic hysteroscopy and simple procedures, maintenance of standard intrauterine pressure is essential for prolonged operative interventions. 
Asia and Oceania are transitioning from gravity bags to pumps at a much slower rate than the global norm. The consensus in Australia is that gravity bags with a pressure cuff work well enough and many hospitals and clinics feel their resources are better allocated towards other priorities. Patient safety regarding fluid management is still not well emphasized. As fluid management increasingly becomes the standard of care, both in Australia and internationally, the trend from gravity bags to pumps will increase. Interestingly, there is a correlation between hysteroscopy and fluid management: medical professionals that are trained in hysteroscopy are more likely to advocate for fluid management equipment to improve patient safety during procedures. As hysteroscopy increases in Australia, it is possible it will act as an incentive to invest in fluid management as well. 
The Australian market value is increasing over the reporting period. It is worth noting that despite an increase in sales projected over the forecast period, the ASP of fluid management systems is remaining stable. Hospitals are leading the trend towards fluid management capital equipment. Hospitals are upgrading from gravity bags to pumps. There is also a small replacement market as hospitals upgrade to pumps with superior technology. Overall, clinics will continue to comprise a small, stable share of the market. Many clinics and physicians are still cost-conscious as the economy is continuing to recover. This has led to hesitation about investing in new products that are non-essential. The growth in fluid management capital equipment will continue to increase, however, the growth in unit sales is expected to mirror the health of the economy overall.
Scope
2013-2023
Companies Mentioned
Cook Medical Cooper Surgical Vitrolife Boston Scientific Karl Storz Johnson & Johnson Olympus Irvine Scientific Coloplast Kitazato Life Global Richard Wolf Carl Zeiss Rocket Medical Stryker Esco Global Merck KGaA - Genea Biomedx Leica Vitromed Merit Medical Systems Medtronic Astec Bio BTG Hunter Scientific Others include: B-bridge International, Inc., FertiPro, Reproline Medical, Nidacon Medical, Pentax, Hologic, Medgyne, Promis Medical, Ecleris, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at 1 comment:

Detailed Study of the China Procedure Numbers for Gynecological Devices

China Procedure Numbers for Gynecological Devices is a new market research publication announced by Reportstack. 
General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Sales numbers are often sensationalized for mainland China. While China’s population is 1.38 billion, the working population (ages 15 to 64) is actually declining. Despite the removal of the One Child policy in 2016, are limiting the country’s growth. The assisted reproduction technology device market provides a well-informed, accurate forecast of procedure cycles and the changes to best practices affecting equipment sales. Understanding the effect of medical tourism also demonstrates the excess capacity and market potential in addition to the drivers and limiters motivating patients to travel for IVF treatments.
The gynecology market value is surprisingly stable, relative to the decreases evident in the global market. China has a cultural history of being cost-sensitive with a preference towards low to mid-end devices. While the shift to higher end devices in China is gradual, the change in purchase trends is causing stability in average sales prices that is unique globally. The high level of competition within China for manufacturers combined with quality changes is bolstering the overall market value beyond changes to unit sales.
The Made in China 2025 plan has identified the high frequency of unnecessary hospital visits within China. The role of a general practitioner as a first line of treatment is largely missing within China’s healthcare system. Attributable to both patient preference and physician salary, the view that hospitals offer superior medical care is prevalent throughout the country. The government is actively restructuring how patients seek medical care to create more physician practices. The expansion of general practices is leading to an increase of in-office medical procedures, and therefore an increase of sales for in-office capital equipment.
Scope
2013-2023
Companies Mentioned
Astec Bio Casmed International Limited Cook Medical Cooper Surgical Esco Global Hunter Scientific Irvine Scientific Kitazato Life Global BRED Lifescience Technology Inc. Medi-Con International Merck KGaA - Genea Biomedx Nidacon Medical* Rocket Medical The Pipette Company Vitromed Vitrolife Karl Storz Olympus Johnson & Johnson Richard Wolf Stryker AngioDynamic Tonglu Zhouji Medical Instruments Co. Ltd China Carnation Endoscope Ltd. Merit Medical Systems Boston Scientific BTG "Medtronic (Smith & Nephew)" Pentax Aohua Hologic Carl Zeiss Kernel Colposcopes ARI Group Alltion Microscopes Co., Ltd. Wallach Surgical Edan Instruments Sunray Medical Coloplast Others include: Shenzhen Sinowares Co., Ltd., B-bridge International, Inc., Reproline Medical, Medtronic, Sigma-Aldrich China, CCD etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
Posted by at No comments:
Subscribe to: Posts (Atom)